Sign in
WithdrawnPhase 1

Lymphatic System Health in Alzheimer's Disease

Key facts

Who runs it
Neurological Associates of West Los Angeles
Where
Los Angeles and Santa Monica, United StatesSee the 2 sites
Trial code
Status
Withdrawn
Phase
Phase 1
Started
10 Dec 2021
Ended
Dec 2023
Type of study
Interventional
Treatments tested
  • Dexmedetomidine
Record updated
28 September 2022
Why it stopped
Pending COVID-19 pandemic

Who can take part

Age
18 years to 90 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • In order for a subject to be considered for this study, the subject must be willing to comply with the study protocol. They must be between 18 and 90 years old. They must complete neurocognitive testing to assess cognitive impairment (QDRS and RBANS)

Who cannot take part

  • Advanced stages of any terminal illness or any active cancer that requires chemotherapy
  • Hepatic impairment
  • Cardiovascular, cerebrovascular, and peripheral vascular arterial thrombosis
  • Significant cytopenia
  • Women who are pregnant, may become pregnant, or are breastfeeding
  • Any counter indications to dexmedetomidine
  • Subjects unable to give informed consent or in vulnerable categories, such as prisoners

Where in United States

  • Westwood Open MRILos Angeles, United States
  • Neurological Associates of West Los AngelesSanta Monica, United States

About the trial

What the trial wants to find out

This study hopes to investigate differences in lymphatic health of patients with Alzheimer's disease by analyzing diffusion-weight images in conscious and sleep states. Dexmedetomidine is a short-acting agent that facilitates a sedated state characterized by slow waves and inhibition of norepinephrine. Conceptually, dexmedetomidine may be preferred to other agents, because it is a short-acting norepinephrine blocker, which could mimic slow wave sleep architecture, opening interstitial spaces, and facilitating plaque removal. Dexmedetomidine may also be preferred given its safety profile among the elderly and acutely ill compared to other anesthetic agents. Sleep will be induced with dexmedetomidine, and interstitial fluid convection will be assessed by measuring free-water diffusion imaging. Freewater diffusion imaging separates out the contributions of extracellular free water and water in the vicinity of cellular tissue; it is used to evaluate abnormalities in extracellular space, such as neuroinflammation, which may contribute to long-term cellular degeneration. This method of analysis could be useful in assessing the lymph systems ability to remove extracellular debris.

The group in the trial

  • DexmedetomidineTreatment being tested

    All patients will complete neurocognitive testing inclusive of the Quick Dementia Rating Scale (QDRS) and Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)) to assess cognitive impairment. A Clinical Dementia Rating (CDR) score of 1 or above will be considered dementia. Lumbar punctures will be used to determine Alzheimer's disease status.The subjects will have three fMRI scans: structural T1 and two NOODI DTI scans. The dexmedetomidine will be given to the patient after the first DTI scan with a dosage that will be congruent with patient height, weight, and medical history.

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
28 September 2022